Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies

Head & Neck
Chih-Chang HungJeff Yi-Fu Chen

Abstract

We have previously shown that p22phox confers resistance to cisplatin in oral squamous cell carcinoma (OSCC). Whether p22phox has clinical correlation with cisplatin resistance and affects the efficacy of other platinum or nonplatinum drugs is unknown. The p22phox expression in tissues and apoptotic markers in cell lines was detected by immunoblotting. The cytotoxicity of chemotherapy drugs was determined by methylthiazol tetrazolium assay. In vivo chemoresistance of p22phox-overexpressing tumors was confirmed by the xenograft mouse model. The p22phox was upregulated in tumors of patients with OSCC refractory to cisplatin treatment. The p22phox overexpression markedly increased the resistance to cisplatin and carboplatin, but not oxaliplatin and 5-fluorouracil (5-FU), in OSCC cells by differentially inhibiting the drug-induced apoptosis. Furthermore, p22phox-dependent resistance to cisplatin, but not 5-FU, was demonstrated in mouse xenograft tumors. The p22phox expression may not only be a prognostic biomarker for prediction of chemotherapy outcomes, but the indication for alternative treatment strategies in oral cancer.

References

Jun 1, 1995·Anti-cancer Drugs·D S Alberts, J K Noel
Nov 8, 2002·Seminars in Oncology·Jim Cassidy, Jean-Louis Misset
Apr 5, 2003·Oral Oncology·C AndreadisD Mouratidou
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Masayasu IwaseMasao Nagumo
Jun 2, 2005·Cellular Signalling·Kendra D MartynUlla G Knaus
Jan 24, 2007·Physiological Reviews·Karen Bedard, Karl-Heinz Krause
Mar 19, 2008·Pathology Oncology Research : POR·Yukihiro HiraishiShigeyuki Fujita
Aug 22, 2008·Oral Oncology·Pol M Specenier, Jan B Vermorken
Jan 1, 2009·Journal of the National Cancer Institute·Victoria HellbergGöran Laurell
Jan 14, 2009·Molecular Cancer Therapeutics·Sarah R McWhinneyHoward L McLeod
Mar 23, 2010·The American Journal of Pathology·Karen BlockHanna E Abboud
Jul 2, 2010·Dalton Transactions : an International Journal of Inorganic Chemistry·Nial J WheateRabbab Oun
Feb 19, 2011·Current Oncology·T Alcindor, N Beauger
Feb 24, 2011·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Lo-Lin TsaiMing-Yung Chou
Mar 3, 2012·Archives of Toxicology·Neife Aparecida Guinaim dos SantosAntonio Cardozo dos Santos
Mar 8, 2013·Hearing Research·Sofia Waissbluth, Sam J Daniel
Dec 24, 2013·The Journal of Biological Chemistry·Mouad EdderkaouiAnna S Gukovskaya
Feb 18, 2015·Oncotarget·Chih-Chang HungJeff Yi-Fu Chen
Feb 18, 2016·Cancer Chemotherapy and Pharmacology·Shahana Dilruba, Ganna V Kalayda

❮ Previous
Next ❯

Citations

Aug 23, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Chih-Chang HungJeff Yi-Fu Chen
Nov 20, 2020·Cellular Oncology (Dordrecht)·Caterina Peraldo-NeiaGiovanna Chiorino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Kohji TakaraKatsuhiko Okumura
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M BenassoM Merlano
© 2022 Meta ULC. All rights reserved